v3.26.1
SEGMENT REPORTING (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting Information [Line Items]    
Total segment revenue $ 367 $ 211,246
Research and development (16,097) (48,709)
Other external costs (6,199) (8,863)
Net income (loss) (23,708) 148,451
Reportable Segment    
Segment Reporting Information [Line Items]    
Total segment revenue 367 211,246
Compensation costs (excluding stock based compensation) (8,190) (13,777)
Other segment items (4,503) (13,158)
Net income (loss) (23,708) 148,451
Rinvatercept program expenses | Reportable Segment    
Segment Reporting Information [Line Items]    
Research and development (2,650) (1,517)
Elritercept program expenses | Reportable Segment    
Segment Reporting Information [Line Items]    
Research and development (3) (18,895)
Cibotercept program expenses | Reportable Segment    
Segment Reporting Information [Line Items]    
Research and development 324 (5,908)
Preclinical & development expenses | Reportable Segment    
Segment Reporting Information [Line Items]    
Research and development (2,006) (1,744)
Other external costs | Reportable Segment    
Segment Reporting Information [Line Items]    
Other external costs $ (7,047) $ (7,796)